To date, two chimeric antigen receptors (CAR)-T cell products from autologous T cells have
been approved by The United States Food and Drug Administration (FDA). The case-by …

T cell engineering, particularly via chimeric antigen receptor (CAR) modifications for
enhancing tumor specificity, has shown efficacy in treating hematologic malignancies. The …

The immune system is permanently confronted with mutated and self-, microbe-, and tumor-
derived neoantigens–as well as other,“unknown” antigens–and has to differentiate between …

CAR-T cell therapy has emerged as a breakthrough therapy for the treatment of relapsed
and refractory hematologic malignancies. However, insufficient CAR-T cell expansion and …

The dynamic roles of T cells in the immune system to recognize and destroy the infected or
mutated cells render T cell therapy a prospective treatment for a variety of diseases …

CRISPR is a customized genome-editing tool that snips DNA in a simpler, cheaper and
more precise way than any other gene editing tool. In recent years CRISPR/Cas has …

Approximately 50% of patients with hematologic malignancies relapse after chimeric antigen
receptor (CAR) T cell treatment; mechanisms of failure include loss of CAR T persistence …

The safety and efficacy of both cell and gene therapies have been demonstrated in
numerous preclinical and clinical trials. Chimeric antigen receptor T (CAR-T) cell therapy …

Adoptive T cell therapies are transforming the treatment of solid and liquid tumors, yet their
widespread adoption is limited in part by the challenge of generating functional cells. T cell …

Adoptive cell therapy (ACT) achieves substantial efficacy in the treatment of hematological
malignancies and solid tumours, while enormous endeavors have been made to reduce …